US Patent Issued to Takeda Pharmaceutical on Sept. 23 for "Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors" (Massachusetts Inventor)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,890, issued on Sept. 23, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors" was invented by Sai Murali Krishna Pulukuri (Sharon, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a small ubiquitin-like modifier (SUMO) activating enzyme (SAE) inhibitor, such as [(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2-thienyl}carbonyl)pyrimidin-4-yl]a...